Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Evaluation of end-of-Life chemotherapy: a medical and economic challenge revealed by a retrospective observational study.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe continuation or discontinuation of oncological care is a critical consideration, particularly due to its implications for quality of life at the end of life. We evaluated the management of cancer patients during the final 90 days of life by measuring the intensity of care and assessing its overall impact.
methodCharacterize care pathways and patient status during the last 90 days of life, including a survival analysis based on Charlson and BARBOT (Pronopall) scores. Care intensity was evaluated using a composite score based on hospitalizations, emergency visits, and ICU admissions. We also compared chemotherapy-treated and untreated patients in terms of survival, care intensity, polypharmacy, and healthcare resource use, focusing on hospitalization and chemotherapy-related costs.
resultsIn total, 270 patients with a median age of 69 (23-96) years were included. During the last 90 days of life, most patients (67.8%) had one or no indicators of high-intensity care. Chemotherapy was administered to 195 patients (72.2%), 80 patients (29.6%) were hospitalized more than once, 38 (14.1%) had multiple emergency department visits, and 5 (1.9%) were admitted to intensive care. Patients who received treatment were significantly younger (p = 0.0058) and in better general condition (p = 0.0129). They were more frequently hospitalized (p = 0.0039), and death occurred more often in hospital wards (p = 0.0223). The total cost of care was significantly higher for treated patients.
conclusionOur findings emphasize the pivotal and potentially detrimental role of chemotherapy administration at the end of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.